James Vredenburgh
Instructor/Lecturer · Yale-New Haven Hospital
Credentials: · · ·
History
- Present
- Present
- 1986–1989
Dartmouth-Hitchcock Medical Center
1983–1986
Research
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Journal of Clinical Oncology · 2009 · 2,000 citations
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
Journal of Clinical Oncology · 2007 · First of 15 authors · Corresponding · 1,096 citations
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
Clinical Cancer Research · 2007 · First of 13 authors · Corresponding · 830 citations
80 papers
75 papers
74 papers · 7 as a fellow
46 papers
41 papers
38 papers
- WP
37 papers
- SG
35 papers
Grants
- 2018
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
National Cancer Institute · P01
Project lead · $4.1M · Duke University
- 1996–1998
Novel Approaches to Stem Cell Transplantation
National Cancer Institute · P01
Project lead · $12.8K · Duke University
Clinical trials
- 2004–2009
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Principal investigator · Completed
Duke University
- 2006–2012
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Study chair · Completed · Phase 2
Duke University
- 2006–2009
Study chair · Completed · Phase 2
Duke University
- 2005–2009
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Study chair · Completed · Phase 2
Duke University